By ParadigMS Foundation
Abstract
The clinical course of multiple sclerosis (MS) is highly variable among patients, thus creating important challenges for the neurologist to appropriately treat and monitor patient progress. Despite some patients having apparently similar symptom severity at MS disease onset, their prognoses may differ greatly. To this end, we believe that a proactive disposition on the part of the neurologist to identify prognostic “red flags” early in the disease course can lead to much better long-term outcomes for the patient in terms of reduced disability and improved quality of life. Here, we present a prognosis tool in the form of a checklist of clinical, imaging and biomarker parameters which, based on consensus in the literature and on our own clinical experiences, we have established to be associated with poorer or improved clinical outcomes. The neurologist is encouraged to use this tool to identify the presence or absence of specific variables in individual patients at disease onset and thereby implement sufficiently effective treatment strategies that appropriately address the likely prognosis for each patient.
This article was published in the scientific journal Frontiers in Immunology, Section Multiple Sclerosis and Neuroimmunology on the 27 September 2022.
Prognosis tool
With this tool we aim to provide neurologists with a practical ‘checklist’ to help establish the likely prognosis of patients based primarily on baseline clinical parameters that can also be reassessed at periodic follow-up visits. The checklist will allow neurologists to identify ‘red flag’ parameters in the MS patient profile that are related to poorer long-term prognosis.
This MS prognosis tool brings together a considerable amount of data specific to each MS patient, thereby providing the MS neurologist with a comprehensive overview of each patient’s current and potential disease status in the future. The tool also should facilitate the development of personalised treatment approaches based on individualised prognostic evidence, enabling outcomes for MS patients to be optimised.
Flyer
Next steps!
We are working to upgrade this checklist into an online tool that HCPs will be able to fill in on their computer. An algorithm will support users by weighting the different criteria to provide increased precision in the final results. This is part of a PhD project that will be rolled out over the next 4 years (2023-2026). Stay tuned for more information!
Download the Scorecard
(PDF, English)
Download the Scorecard
(Word, English)
Author contributions
Authors: Bart Van Wijmeersch1, Hans-Peter Hartung2, Patrick Vermersch3, Maura Pugliatti4, Carlo Pozzilli5, Nikolaos Grigoriadis6, Mona Alkhawajah7, Laura Airas8, Ralf Linker9, and Celia Oreja-Guevara10
1) University MS Centre, Belgium; Noorderhart, Rehabilitation and MS, Pelt, Belgium; University of Hasselt, Belgium 2) Department of Neurology, Faculty of Medicine, Heinrich Heine University, Germany; Brain and Mind Centre, The University of Sydney, Australia; Medical University Vienna, Austria; Palacký University, Olomouc, Czechia 3) Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, France 4) Department of Neuroscience and Rehabilitation, University Hospital of Ferrara, Italy; Unit of Clinical Neurology, S. Anna University Hospital, Italy 5) Dept Human Neuroscience, Sapienza University, Italy 6) B’ Dept of Neurology, Aristotle University of Thessaloniki, Greece 7) King Faisal Specialist Hospital & Research Centre, Saudi Arabia 8) Turku University Hospital and University of Turku, Finland 9) Department of Neurology, University Hospital Regensburg, Germany 10) Department of Neurology, Hospital Clínico San Carlos, IDISSC, Spain; Department of Medicine, Faculty of Medicine, Universidad Complutense de Madrid, Spain
Development of the tool was led by Bart Van Wijmeersch, with input from all other authors at regular meetings. Bart Van Wijmeersch wrote the manuscript, with feedback on early versions provided by Hans-Peter Hartung and Celia Oreja-Guevara.
All authors contributed to manuscript revision and read and approved the submitted version.
Funding
Medical writing support for the preparation of this manuscript along with the payment of publishing fees were provided by the ParadigMS Foundation.
Acknowledgments
The creation and communication of educational materials by the ParadigMS Foundation was sponsored by Sanofi, Roche, and Merck in the year of publishing the Article.
The dissemination activities linked to the prognosis tool in 2022, have been funded by a grant of Sanofi Belgium.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
©The table (prognosis tool) contains the same content as that in the published paper (available at the Frontiers of Immunology website) and distributed under the Creative Commons license agreement.
